2021年1月22日 · Background: SM-88 (racemetyrosine, Tyme Inc) is a dysfunctional tyrosine derivative used with MPS (methoxsalen 10mg, phenytoin 50mg and sirolimus 0.5mg). SM-88 was well tolerated with improvement in survival among select heavily pretreated PDAC patients who achieved stable disease (HR 0.08, p = 0.02) (Noel et al. Annal Oncol 2019).

今天，FDA宣布，授予创新药物SM-88（racemetyrosine）授予了 孤儿药 地位，用于治疗胰腺癌患者。 这标志着SM-88是基于癌症代谢的化合物研发中出现的一个重要里程碑！

2021年11月4日 · racemetyrosine (SM-88)是一种新型的联合疗法，包括四种药物，由酪氨酸衍生物（D，L-α-甲基酪氨酸），mTOR抑制剂（西罗莫司），CYP3a4诱导剂（苯妥英）和氧化应激催化剂（甲氧沙林）组成。

2019年7月8日 · 香港港安肿瘤中心特讯：近日宣布，其在研药物组合SM-88，作为单药疗法，在治疗晚期胰腺癌患者的开放标签，多中心2期临床试验TYME-88-Panc中，与历史数据相比，显著延长患者的总生存期 (OS)，并展示了良好的耐受性和安全性。

The Savoia-Marchetti SM.88, was an Italian twin-engined, three-seat, heavy fighter prototype of World War II, featuring a twin-boom structure, and powered by German Daimler-Benz DB 601 engines. The SM.88, intended for export, was a land-based, multi-role heavy fighter regarded as an advanced combat aircraft at the time of its debut in 1939.

2018年2月26日 · Background: SM-88 (tyrosine derivative, mTOR inhibitor, CYP3a4 inducer and oxidative stress catalyst) is a relatively non-toxic, targeted therapy that utilizes the Warburg Effect in combination with oxidative stress to cause tumor cell death.

Tyme是一家基于癌症代谢疗法的生物技术公司，近日宣布，评估SM-88（外消旋酪氨酸）单药治疗晚期胰腺癌患者的II期TYME-88-Panc研究表现出令人鼓舞的有效性和安全性。

Purpose SM-88 (D,L-alpha-metyrosine; racemetyrosine) is a novel anti-cancer agent, used with melanin, phenytoin, and sirolimus (SMK Therapy). This pilot first-in-human study characterized the safety, tolerability, and efficacy of SMK Therapy in subjects with advanced metastatic cancer.

Background: This trial explores SM-88 used with methoxsalen, phenytoin, and sirolimus (MPS) in pretreated metastatic pancreatic ductal adenocarcinoma (mPDAC) METHODS: Forty-nine patients were randomized to daily 460 or 920 mg oral SM-88 with MPS (SM-88 Regimen). The primary endpoint was objective response rate (RECIST 1.1).

Racemetyrosine (SM-88) is an amino-acid analogue used with methoxsalen, phenytoin, and sirolimus (MPS) to enhance SM-88 activity. Method A phase 1b/2, open-label trial in BRPC and rising PSA. Patients were given daily SM-88 (230 mg BID), methoxsalen (10 mg), phenytoin (50 mg), and sirolimus (0.5 mg)).